COVID-19 and rheumatology: A year later

Белов, Б. С.; Лила, А. М.

doi:10.47360/1995-4484-2021-31-36

Cited by 7 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…, поразила более 150 млн человек во всех регионах земного шара и привела более чем к 3 млн летальных исходов [2]. За время, прошедшее с начала пандемии, было проведено беспрецедентное число клинических и экспериментальных исследований, привлекших пристальное внимание к ревматологическим проблемам COVID-19, что в свою очередь во многом способствовало совершенствованию подходов к ведению пациентов [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17].…”

unclassified

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Насонов

Лила

Мазуров

et al. 2021

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

In mid-2021, the SARS-CoV-2 (Severe Acute Respiratory coronavirus 2) infection, which caused the coronavirus disease (COVID-19) pandemic, affected more than 157 million people in all regions of the world and led to more than 3.2 million deaths. It is assumed that elderly age, uncontrolled inflammation, anti-inflammatory therapy, comorbid pathology, genetic and other factors can potentially lead to an increase in “sensitivity” to viral and bacterial infections, including SARS-CoV-2. The new version of the recommendations of the Association of Rheumatologists of Russia formulates the main provisions concerning the tactics of managing patients with Immune-mediated Rheumatic Diseases during the ongoing COVID-19 pandemic.

show abstract

unclassified

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Насонов

Лила

Мазуров

et al. 2021

Naučno-praktičeskaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

show abstract

Rheumatic diseases and coronavirus infection: levilimab use experience

Калинина

Lekareva

Zvonorenko

et al. 2021

Medicinskij alfavit

View full text Add to dashboard Cite

Background. Rheumatic diseases (RD) of autoimmune origin are considered as an important risk factor for infectious processes due to characteristic native immune system disorder, as well as due to the adverse effect of immunosuppressants and glucocorticoids on the mechanisms of anti-infective protection.Aim. To highlight the problem of RD and concomitant viral infection which becomes critical in the era of COVID‑19.Results. According to the current national guidelines for the management of patients with COVID‑19, patients with RD represent an increased risk group for the adverse course of coronavirus infection. Presented article provides basic information on the use of interleukin‑6 (IL‑6) inhibitors in patients with COVID‑19 focusing on the benefit of this therapeutic option in those with prior RD. The article presents an analysis of two clinical cases demonstrating high efficacy and good tolerability of levilimab (Ilsira®) in the treatment of coronavirus pneumoniae in the setting of autoimmune diseases: polymyositis (PM) and rheumatoid arthritis (RA).Conclusion. Our own clinical experience confirms the feasibility of including an IL‑6 receptor inhibitor in the treatment regimen for coronavirus pneumonia in patients with RD characterized of immune inflammation.

show abstract

Giant cell arteritis in conditions of coronavirus infection (clinical case)

Бабаева

Lekareva

Kalinina

et al. 2022

Medicinskij alfavit

View full text Add to dashboard Cite

The complexity of timely diagnosis of giant cell arteritis (GCA), as the most common form of systemic vasculitis in the elderly, is due to the nonspecificity of clinical manifestations and the absence of specific immunological markers. New difficulties arise during the period of coronavirus infection, which manifests itself in similar syndromes and at the same time can provoke immuno-inflammatory rheumatic disease. In this regard, it is extremely important to make a correct differential diagnosis between persistent viral infection and the development of systemic vasculitis. This article presents a clinical observation demonstrating the complex process of diagnosis and differential diagnosis of GCA in the conditions of the COVID-19 pandemic. The patient was hospitalized due to a confirmed coronavirus infection. However, despite the standard therapy and the achieved eradication of the coronavirus, the symptoms characteristic of GCA and polymyalgia rheumatica (PR) persisted. A precision analysis of the clinical picture allowed us to establish that the typical manifestations of GCA and PR occurred in the period preceding COVID-19 infection. Subsequent in-depth examination made it possible to verify the diagnosis of GCA and PR based on the current classification criteria. The therapy with glucocorticoid and methotrexate made it possible to achieve remission. The presented observation will help to raise awareness of general practitioners and related specialties about the need to rule out GCA and PR in the case of prolonged unexplained fever, myalgia, headache, joint pain and swelling, transient visual disturbances, jaw claudication in elderly patients in the setting or after coronavirus infection.

show abstract

COVID-19 and rheumatology: A year later

Cited by 7 publications

References 30 publications

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia

Rheumatic diseases and coronavirus infection: levilimab use experience

Giant cell arteritis in conditions of coronavirus infection (clinical case)

Contact Info

Product

Resources

About